JP2013209421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013209421A5 JP2013209421A5 JP2013124713A JP2013124713A JP2013209421A5 JP 2013209421 A5 JP2013209421 A5 JP 2013209421A5 JP 2013124713 A JP2013124713 A JP 2013124713A JP 2013124713 A JP2013124713 A JP 2013124713A JP 2013209421 A5 JP2013209421 A5 JP 2013209421A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- live attenuated
- virus
- kit
- attenuated virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000700605 Viruses Species 0.000 claims 39
- 230000002238 attenuated effect Effects 0.000 claims 28
- 239000000126 substance Substances 0.000 claims 20
- 102000007562 Serum Albumin Human genes 0.000 claims 15
- 108010071390 Serum Albumin Proteins 0.000 claims 15
- 230000002779 inactivation Effects 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 230000003612 virological effect Effects 0.000 claims 12
- 102000009027 Albumins Human genes 0.000 claims 11
- 108010088751 Albumins Proteins 0.000 claims 11
- 150000001720 carbohydrates Chemical class 0.000 claims 9
- 241000710781 Flaviviridae Species 0.000 claims 8
- 229920005682 EO-PO block copolymer Polymers 0.000 claims 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 6
- 241000712892 Arenaviridae Species 0.000 claims 6
- 241000711573 Coronaviridae Species 0.000 claims 6
- 241000711950 Filoviridae Species 0.000 claims 6
- 241000700586 Herpesviridae Species 0.000 claims 6
- 241000712464 Orthomyxoviridae Species 0.000 claims 6
- 241000711504 Paramyxoviridae Species 0.000 claims 6
- 241000150350 Peribunyaviridae Species 0.000 claims 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 6
- 241000700625 Poxviridae Species 0.000 claims 6
- 241000712907 Retroviridae Species 0.000 claims 6
- 241000711931 Rhabdoviridae Species 0.000 claims 6
- 241000710924 Togaviridae Species 0.000 claims 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 6
- 229920001983 poloxamer Polymers 0.000 claims 6
- 102000004407 Lactalbumin Human genes 0.000 claims 5
- 108090000942 Lactalbumin Proteins 0.000 claims 5
- 229920002517 Poloxamer 338 Polymers 0.000 claims 5
- 229920002025 Pluronic® F 88 Polymers 0.000 claims 3
- 229920002065 Pluronic® P 105 Polymers 0.000 claims 3
- 229960000502 poloxamer Drugs 0.000 claims 3
- 229940106032 poloxamer 335 Drugs 0.000 claims 3
- 208000001490 Dengue Diseases 0.000 claims 2
- 206010012310 Dengue fever Diseases 0.000 claims 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims 2
- 206010041896 St. Louis Encephalitis Diseases 0.000 claims 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 2
- 208000003152 Yellow Fever Diseases 0.000 claims 2
- 208000025729 dengue disease Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91057907P | 2007-04-06 | 2007-04-06 | |
| US60/910,579 | 2007-04-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010502331A Division JP5296775B2 (ja) | 2007-04-06 | 2008-04-04 | 弱毒生ウイルスのための方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015245040A Division JP2016041753A (ja) | 2007-04-06 | 2015-12-16 | 弱毒生ウイルス組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013209421A JP2013209421A (ja) | 2013-10-10 |
| JP2013209421A5 true JP2013209421A5 (enExample) | 2014-03-13 |
Family
ID=39827288
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010502331A Active JP5296775B2 (ja) | 2007-04-06 | 2008-04-04 | 弱毒生ウイルスのための方法および組成物 |
| JP2013124713A Withdrawn JP2013209421A (ja) | 2007-04-06 | 2013-06-13 | 弱毒生ウイルス組成物 |
| JP2015245040A Withdrawn JP2016041753A (ja) | 2007-04-06 | 2015-12-16 | 弱毒生ウイルス組成物 |
| JP2019105370A Active JP6817370B2 (ja) | 2007-04-06 | 2019-06-05 | 弱毒生ウイルス組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010502331A Active JP5296775B2 (ja) | 2007-04-06 | 2008-04-04 | 弱毒生ウイルスのための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015245040A Withdrawn JP2016041753A (ja) | 2007-04-06 | 2015-12-16 | 弱毒生ウイルス組成物 |
| JP2019105370A Active JP6817370B2 (ja) | 2007-04-06 | 2019-06-05 | 弱毒生ウイルス組成物 |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US8084039B2 (enExample) |
| EP (2) | EP2144998B1 (enExample) |
| JP (4) | JP5296775B2 (enExample) |
| KR (4) | KR101562971B1 (enExample) |
| CN (4) | CN101679954A (enExample) |
| AU (1) | AU2008279576C1 (enExample) |
| BR (1) | BRPI0809663B8 (enExample) |
| CA (1) | CA2720570C (enExample) |
| CO (1) | CO6260150A2 (enExample) |
| CU (1) | CU20090169A7 (enExample) |
| CY (1) | CY1118958T1 (enExample) |
| DK (1) | DK2144998T3 (enExample) |
| ES (1) | ES2621511T3 (enExample) |
| HK (1) | HK1217168A1 (enExample) |
| HR (1) | HRP20170513T1 (enExample) |
| HU (1) | HUE031617T2 (enExample) |
| IL (3) | IL201429A (enExample) |
| LT (1) | LT2144998T (enExample) |
| MX (2) | MX360728B (enExample) |
| MY (3) | MY180465A (enExample) |
| NZ (2) | NZ580978A (enExample) |
| PH (1) | PH12015500773B1 (enExample) |
| PL (1) | PL2144998T3 (enExample) |
| PT (1) | PT2144998T (enExample) |
| SG (2) | SG10201913741YA (enExample) |
| SI (1) | SI2144998T1 (enExample) |
| WO (1) | WO2009014774A1 (enExample) |
| ZA (2) | ZA200907790B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2144998T1 (sl) * | 2007-04-06 | 2017-05-31 | Takeda Vaccines, Inc. | Postopki in sestavki za žive atenuirane viruse |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| US7998488B2 (en) | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
| MY178195A (en) * | 2008-12-05 | 2020-10-06 | Takeda Vaccines Inc | Compositions, methods and uses for inducing viral growth |
| PL2471518T3 (pl) | 2009-05-18 | 2018-01-31 | Sigmoid Pharma Ltd | Kompozycja zawierająca kropelki oleju |
| BR112012002963A2 (pt) | 2009-08-12 | 2017-10-24 | Sigmoid Pharma Ltd | composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa |
| EA201390812A1 (ru) * | 2010-12-02 | 2013-11-29 | Онколитикс Байотек Инк. | Лиофилизированные вирусные составы |
| MX373096B (es) | 2010-12-02 | 2020-04-27 | Oncolytics Biotech Inc | Formulaciones virales líquidas. |
| US20120219590A1 (en) * | 2011-02-24 | 2012-08-30 | Paxvax, Inc. | Formulations useful for spray drying vaccines |
| CA2837145A1 (en) * | 2011-05-26 | 2012-11-29 | Glaxosmithkline Biologicals Sa | Inactivated dengue virus vaccine |
| EP2726606A1 (en) * | 2011-06-28 | 2014-05-07 | Leukocare Ag | Novel stabilisation method for viruses or bacteria |
| EP2802649B1 (en) | 2012-01-09 | 2017-08-09 | Sanofi Pasteur Biologics, LLC | Purification of herpes virus |
| CA2873775C (en) | 2012-05-21 | 2021-04-20 | Sanofi Pasteur Limited | Herpesvirus compositions and related methods |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| SG10201801459SA (en) | 2013-03-14 | 2018-03-28 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
| US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
| US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| EP3060247A1 (en) * | 2013-10-25 | 2016-08-31 | Leukocare Ag | A novel method for the production of stabile vaccines |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
| TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
| CN103877565A (zh) * | 2014-02-24 | 2014-06-25 | 黄淮学院 | 治疗膀胱癌的基因针剂及其制备方法 |
| PL3215127T3 (pl) | 2014-11-07 | 2021-05-17 | Sublimity Therapeutics Limited | Kompozycje zawierające cyklosporynę |
| KR20230107375A (ko) * | 2014-12-18 | 2023-07-14 | 암젠 인크 | 안정한 동결된 단순 포진 바이러스 제제 |
| CN107614008A (zh) * | 2015-03-20 | 2018-01-19 | 蓝鸟生物公司 | 载体制剂 |
| CN104984357B (zh) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
| TWI569806B (zh) * | 2015-06-10 | 2017-02-11 | 輔英科技大學 | Stabilizer compositions for vaccines and methods for their preparation and swine fever vaccine containing the same |
| WO2017056101A1 (en) | 2015-09-30 | 2017-04-06 | Panacea Biotec Limited | Stable live attenuated recombinant dengue vaccine |
| WO2017109698A1 (en) * | 2015-12-22 | 2017-06-29 | Glaxosmithkline Biologicals Sa | Immunogenic formulation |
| AR107262A1 (es) * | 2016-01-27 | 2018-04-11 | Lilly Co Eli | Inactivación de patógenos por delipidación |
| JP6376578B2 (ja) * | 2016-02-18 | 2018-08-22 | 学校法人慶應義塾 | 細胞培養培地、培養方法、及びオルガノイド |
| US11311487B2 (en) | 2016-04-14 | 2022-04-26 | Trizell Ltd. | Viral vector stabilization |
| CN105925541A (zh) * | 2016-05-13 | 2016-09-07 | 云南省畜牧兽医科学院 | 一种蓝舌病病毒冻存保护剂及冻存方法 |
| TWI766876B (zh) * | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
| JP7406377B2 (ja) * | 2017-05-15 | 2023-12-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定なウイルス含有組成物 |
| CN107475204A (zh) * | 2017-08-03 | 2017-12-15 | 中国人民解放军军事医学科学院军事兽医研究所 | 一种囊膜病毒保护剂及其制备方法 |
| CN107233576B (zh) * | 2017-08-08 | 2020-02-07 | 江苏省农业科学院 | 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用 |
| EP3704233A4 (en) * | 2017-11-01 | 2021-08-04 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF THE CYTOMEGALOVIRUS |
| UA129245C2 (uk) | 2017-12-07 | 2025-02-26 | Мерк Шарп Енд Доум Елелсі | Склад вакцинної композиції від вірусу денге |
| JP7437385B2 (ja) * | 2018-09-06 | 2024-02-22 | バヴァリアン・ノルディック・アクティーゼルスカブ | 保管が改善されたポックスウイルス組成物 |
| WO2020113197A1 (en) * | 2018-11-30 | 2020-06-04 | Vaccine Stabilization Institute | Viral formulations containing amino acids |
| MX2021007639A (es) | 2018-12-27 | 2021-08-11 | Amgen Inc | Formulaciones de virus liofilizadas. |
| CA3109897A1 (en) * | 2020-04-11 | 2021-06-10 | Qiyi Xie | Vaccination against coronavirus with poliomyelitis vaccine |
| US20210322542A1 (en) * | 2020-04-11 | 2021-10-21 | Qiyi Xie | Vaccination against coronavirus with poliomyelitis vaccine |
| WO2022037248A1 (en) * | 2020-08-19 | 2022-02-24 | Versitech Limited | Live attenuated sars-cov-2 virus immunogenic compositions, methods of making and using |
| WO2024073860A1 (en) * | 2022-10-07 | 2024-04-11 | Elarex Inc. | Stabilization of virus-based therapeutic agent |
| WO2025106787A1 (en) * | 2023-11-17 | 2025-05-22 | Sanofi Pasteur Inc. | Trehalose vaccine formulation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2505657A1 (fr) | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| FR2742756B1 (fr) * | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
| US6616931B1 (en) | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| KR20010022452A (ko) * | 1997-07-31 | 2001-03-15 | 추후제출 | 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신 |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| US6163606A (en) * | 1998-09-16 | 2000-12-19 | Lucent Technologies Inc. | System for providing virtual called party identification in a voice mail system |
| CN1053590C (zh) | 1998-10-19 | 2000-06-21 | 卫生部长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
| CN1062770C (zh) * | 1998-11-12 | 2001-03-07 | 卫生部长春生物制品研究所 | 甲肝-麻疹二联疫苗及其生产方法 |
| WO2000066710A2 (en) | 1999-05-04 | 2000-11-09 | Eric Edward Worrall | Method for the preservation of viruses and mycoplasma |
| US6432411B1 (en) * | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
| WO2001060847A2 (en) * | 2000-02-16 | 2001-08-23 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Avirulent, immunogenic flavivirus chimeras |
| AT410634B (de) * | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| CA2469623C (en) * | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| CN1909922B (zh) * | 2002-02-26 | 2013-08-21 | 阿尔特拉瓦克斯股份有限公司 | 新的黄病毒抗原 |
| US8293530B2 (en) | 2006-10-17 | 2012-10-23 | Carnegie Mellon University | Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom |
| WO2003086443A1 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| AU2003247337B2 (en) * | 2002-04-11 | 2007-09-06 | Medimmune, Llc | Preservation of bioactive materials by freeze dried foam |
| JP4515098B2 (ja) | 2002-04-15 | 2010-07-28 | 哲夫 山東 | 皮膚炎治療用クリーム |
| GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| US6873807B2 (en) * | 2003-03-20 | 2005-03-29 | Kabushiki Kaisha Toshiba | Image forming apparatus |
| US7588774B2 (en) * | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
| US7294455B2 (en) * | 2003-05-16 | 2007-11-13 | The University Of North Carolina At Chapel Hill | Fixed-dried platelets cross-linked to protein |
| BRPI0417225A (pt) * | 2003-12-05 | 2007-03-06 | Becton Dickinson Co | métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos |
| US20050202046A1 (en) | 2004-03-11 | 2005-09-15 | Wyeth | Canine vaccine for protection against ehrlichiosis |
| US20050276785A1 (en) | 2004-06-09 | 2005-12-15 | Schering Aktiengesellschaft | Treatment of cardiomyopathy and of endothelial dysfunction |
| EP1645283A1 (en) * | 2004-10-08 | 2006-04-12 | Chiron Behring GmbH & Co. KG | Combination vaccine |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| SI2144998T1 (sl) * | 2007-04-06 | 2017-05-31 | Takeda Vaccines, Inc. | Postopki in sestavki za žive atenuirane viruse |
-
2008
- 2008-04-04 SI SI200831786A patent/SI2144998T1/sl unknown
- 2008-04-04 CN CN200880018784A patent/CN101679954A/zh active Pending
- 2008-04-04 MY MYPI2014001569A patent/MY180465A/en unknown
- 2008-04-04 EP EP08826570.7A patent/EP2144998B1/en active Active
- 2008-04-04 HR HRP20170513TT patent/HRP20170513T1/hr unknown
- 2008-04-04 JP JP2010502331A patent/JP5296775B2/ja active Active
- 2008-04-04 KR KR1020097023223A patent/KR101562971B1/ko active Active
- 2008-04-04 SG SG10201913741YA patent/SG10201913741YA/en unknown
- 2008-04-04 KR KR1020157017020A patent/KR20150082667A/ko not_active Ceased
- 2008-04-04 US US12/098,077 patent/US8084039B2/en active Active
- 2008-04-04 KR KR1020177008394A patent/KR20170038110A/ko not_active Ceased
- 2008-04-04 MY MYPI20094159A patent/MY156422A/en unknown
- 2008-04-04 PL PL08826570T patent/PL2144998T3/pl unknown
- 2008-04-04 CA CA2720570A patent/CA2720570C/en active Active
- 2008-04-04 LT LTEP08826570.7T patent/LT2144998T/lt unknown
- 2008-04-04 KR KR1020187009180A patent/KR102134980B1/ko active Active
- 2008-04-04 MX MX2012010788A patent/MX360728B/es unknown
- 2008-04-04 NZ NZ580978A patent/NZ580978A/en unknown
- 2008-04-04 MY MYPI2018000785A patent/MY200568A/en unknown
- 2008-04-04 SG SG10201508397VA patent/SG10201508397VA/en unknown
- 2008-04-04 CN CN201910649078.9A patent/CN110478479B/zh active Active
- 2008-04-04 CN CN201510325174.XA patent/CN104998257A/zh active Pending
- 2008-04-04 NZ NZ600958A patent/NZ600958A/en unknown
- 2008-04-04 HU HUE08826570A patent/HUE031617T2/en unknown
- 2008-04-04 PT PT88265707T patent/PT2144998T/pt unknown
- 2008-04-04 BR BRPI0809663A patent/BRPI0809663B8/pt active IP Right Grant
- 2008-04-04 ES ES08826570.7T patent/ES2621511T3/es active Active
- 2008-04-04 WO PCT/US2008/059472 patent/WO2009014774A1/en not_active Ceased
- 2008-04-04 CN CN201410106277.2A patent/CN104083757A/zh active Pending
- 2008-04-04 AU AU2008279576A patent/AU2008279576C1/en active Active
- 2008-04-04 EP EP15001669.9A patent/EP2940129B1/en active Active
- 2008-04-04 DK DK08826570.7T patent/DK2144998T3/en active
- 2008-04-04 MX MX2009010798A patent/MX2009010798A/es active IP Right Grant
-
2009
- 2009-10-06 CU CU20090169A patent/CU20090169A7/es unknown
- 2009-10-11 IL IL201429A patent/IL201429A/en active IP Right Grant
- 2009-11-03 CO CO09123789A patent/CO6260150A2/es not_active Application Discontinuation
- 2009-11-05 ZA ZA2009/07790A patent/ZA200907790B/en unknown
-
2011
- 2011-11-18 US US13/300,217 patent/US20140302091A1/en not_active Abandoned
-
2013
- 2013-06-13 JP JP2013124713A patent/JP2013209421A/ja not_active Withdrawn
- 2013-08-21 IL IL228065A patent/IL228065B/en active IP Right Grant
-
2014
- 2014-01-30 ZA ZA2014/00725A patent/ZA201400725B/en unknown
-
2015
- 2015-04-07 PH PH12015500773A patent/PH12015500773B1/en unknown
- 2015-12-16 JP JP2015245040A patent/JP2016041753A/ja not_active Withdrawn
-
2016
- 2016-04-27 HK HK16104804.0A patent/HK1217168A1/zh unknown
- 2016-07-22 US US15/194,297 patent/US10525120B2/en active Active
- 2016-10-26 IL IL24852216A patent/IL248522B/en active IP Right Grant
-
2017
- 2017-04-04 CY CY20171100402T patent/CY1118958T1/el unknown
-
2019
- 2019-06-05 JP JP2019105370A patent/JP6817370B2/ja active Active
- 2019-11-22 US US16/692,488 patent/US11197923B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013209421A5 (enExample) | ||
| JP2019172686A5 (enExample) | ||
| HRP20170513T1 (hr) | Postupci i pripravci za žive oslabljene viruse | |
| Patil et al. | Evaluation of platelet augmentation activity of Carica papaya leaf aqueous extract in rats | |
| Seghatchian et al. | Main properties of the THERAFLEX MB-plasma system for pathogen reduction | |
| Ison | Influenza prevention and treatment in transplant recipients and immunocompromised hosts | |
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| MY194294A (en) | Novel viral replication inhibitors | |
| Morfini et al. | Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| JP2016513658A5 (enExample) | ||
| Giardino et al. | SARS-CoV-2 infection in the immunodeficient host: necessary and dispensable immune pathways | |
| BR112020023675A2 (pt) | diltiazem para uso no tratamento de infecções microbianas | |
| Abbas | Hepatitis D in pakistan | |
| JP2008505901A5 (enExample) | ||
| JP2018523648A5 (enExample) | ||
| Vargas-Soler et al. | Measles in pediatrics: the resurgence of a vaccine-preventable disease | |
| Sahin et al. | A child with an unusual complication of Crimean-Congo hemorrhagic fever: Hemorrhagic pleural effusion | |
| Rabbad et al. | Prevalence of hepatitis G virus infection among chronic hepatitis B, chronic hepatitis C and HIV patients in Sana'a, Yemen | |
| Al-Greti | Prevalence of hepatitis C virus in beta-thalassemia major patients at Karbala governorate | |
| Kishor et al. | A review ON etio-pathogenesis OF dengue fever and its management-an updated review | |
| Pithon | Severe hemorrhage in a patient with dengue hemorrhagic fever after insertion of orthodontic mini-implants. A case report | |
| Akar | A note on oseltamivir treatment in a boy with G6PD deficiency | |
| Wexler et al. | Reversal of warfarin-associated life-threatening bleed with an attenuated dose of 4-factor prothrombin complex concentrate | |
| Trevejo et al. | Safety and efficacy of the monoclonal antibody VIS410 in a human volunteer challenge model of infection with an H1N1 Influenza A virus |